Last updated on July 2019

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis


Brief description of study

Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis

Detailed Study Description

The aim of the current study to assess the efficacy of voclosporin in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin over 24 weeks in subjects with FSGS.

Clinical Study Identifier: NCT03598036

Find a site near you

Start Over

FSGS Investigative Center

El Paso, TX United States
  Connect »

FSGS Investigative Center

Denver, CO United States
  Connect »

FSGS Investigative Center

Winter Park, FL United States
  Connect »

FSGS Investigative Center

Lawrenceville, GA United States
  Connect »

FSGS Investigative Center

Louisville, KY United States
  Connect »

FSGS Investigative Center

Shreveport, LA United States
  Connect »

FSGS Investigative Center

Detroit, MI United States
  Connect »

FSGS Investigative Center

Minneapolis, MN United States
  Connect »

FSGS Investigative Centre

Saint Louis, MO United States
  Connect »

FSGS Investigative Center

Newark, NJ United States
  Connect »

FSGS Investigative Center

New York, NY United States
  Connect »

FSGS Investigative Center

Chapel Hill, NC United States
  Connect »

FSGS Investigative Center

Charlotte, NC United States
  Connect »

FSGS Investigative Center

Columbus, OH United States
  Connect »

FSGS Investigative Center

Bethlehem, PA United States
  Connect »

FSGS Investigative Center

Dallas, TX United States
  Connect »

FSGS Investigative Site

Salt Lake City, UT United States
  Connect »

FSGS Investigative Centre

Santiago De Los Caballeros, Dominican Republic
  Connect »